Frequently Asked Questions
The market is segmented based on , By Product Type (Instrument, Consumables and Accessories, Software and Service), Test Type (Imaging, Biopsy, Tumor Biomarkers Tests, Genetic Tests, Endoscopy, Immunohistochemistry, Others), Technology (Instrument Based, Platform-Based, Tumor Biomarker Tests), Application (Breast Cancer, Prostate Cancer, Colorectal Cancer, Lung Cancer, Skin Cancer, Kidney Cancer, Blood Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Others), Age Group (Adult, Pediatric), End-User (Hospitals, Oncology Speciality Clinics, Diagnostic Laboratories, Cancer Research Institutes, Others), Distribution Channel (Direct tenders, Retail Sales) – Industry Trends and Forecast to 2030.
.
The Europe Cancer Diagnostics Market size was valued at USD 18369.60 USD Million in 2022.
The Europe Cancer Diagnostics Market is projected to grow at a CAGR of 6.8% during the forecast period of 2023 to 2030.
The major players operating in the market include General Electric, Abbott, Hologic , Agilent Technologies , F. Hoffmann-La Roche Ltd, FUJIFILM Corporation, Danaher, DiaSorin S.P.A., Myriad Genetics , Siemens Healthcare GmbH, BD, bioMérieux, Bio-Rad Laboratories , Cancer Diagnostics , Vela Diagnostics, AMOY Diagnostics CO. , Quidel Corporation, Bio SB, Biocartis, Exact Science
.
The market report covers data from the Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe.
